Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

10.18
+0.45004.62%
Pre-market: 10.290.1100+1.08%06:12 EST
Volume:6.97M
Turnover:68.79M
Market Cap:1.18B
PE:-2.39
High:10.26
Open:9.59
Low:9.38
Close:9.73
52wk High:28.25
52wk Low:5.90
Shares:115.83M
Float Shares:102.00M
Volume Ratio:0.58
T/O Rate:6.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2519
EPS(LYR):-5.2506
ROE:-52.11%
ROA:-28.51%
PB:1.58
PE(LYR):-1.94

Loading ...

Wolfe downgrades Intellia to Peer Perform on Nex-z safety issue

TIPRANKS
·
1 hour ago

Stock Track | Intellia Therapeutics Surges 5.04% Despite Multiple Analyst Downgrades

Stock Track
·
14 hours ago

Stock Track | Intellia Therapeutics Surges 5% Despite Analyst Downgrades, Defying Market Expectations

Stock Track
·
14 hours ago

Intellia Therapeutics Cut to Hold From Buy by Jones Trading

Dow Jones
·
15 hours ago

Intellia Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Yesterday

JonesTrading downgrades Intellia Therapeutics (NTLA) to a Hold

TIPRANKS
·
Yesterday

Intellia Therapeutics Inc : Jonestrading Cuts to Hold Rating

THOMSON REUTERS
·
Yesterday

Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Yesterday

Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial

TIPRANKS
·
Yesterday

Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy

Reuters
·
Yesterday

Truist Cuts Price Target on Intellia Therapeutics to $14 From $25, Keeps Buy Rating

MT Newswires Live
·
Nov 10

Intellia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 10

Intellia Therapeutics Inc : H.c. Wainwright Cuts Target Price to $15 From $18

THOMSON REUTERS
·
Nov 10

Intellia Therapeutics presents Phase 1/2 data on lonvo-z

TIPRANKS
·
Nov 10

More Drugs to Fight High Cholesterol Are Emerging -- WSJ

Dow Jones
·
Nov 09

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

GlobeNewswire
·
Nov 09

J.P. Morgan downgrades Intellia Therapeutics (NTLA) to a Sell

TIPRANKS
·
Nov 08

RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating

MT Newswires Live
·
Nov 08

BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive

Reuters
·
Nov 08

BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT

Reuters
·
Nov 07